Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
15 hedge funds and large institutions have $495K invested in Iterum Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 6 closing their positions.
4.31% less ownership
Funds ownership: 6.92% → 2.61% (-4.3%)
17% less funds holding
Funds holding: 18 → 15 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
65% less capital invested
Capital invested by funds: $1.43M → $495K (-$936K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55.7K |
| 2 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$193 |
| 3 |
PCMC
Planning Capital Management Corporation
Paoli,
Pennsylvania
|
+$58 |
| 4 |
NLVP
New Leaf Venture Partners
New York
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$668K |
| 2 |
Renaissance Technologies
New York
|
-$67.1K |
| 3 |
Millennium Management
New York
|
-$43.2K |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
-$23.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17.4K |
ITRM Hedge Fund Activity: Q2 2024 in Review
15 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q2 2024, worth a combined $495K — down 65% from $1.43M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ITRM and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $55.7K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $668K sold.
- 15 institutional investors held Iterum Therapeutics (ITRM) as of Q2 2024, down from 18 in Q1 2024.
- Funds reported $495K of Iterum Therapeutics stock for Q2 2024, down 65% quarter-over-quarter.
- 3 funds opened new Iterum Therapeutics positions in Q2 2024 and 6 closed out, a net change of -3 holders.
- The largest Iterum Therapeutics buyer in Q2 2024 was Susquehanna International Group, an estimated $55.7K added.
- The largest Iterum Therapeutics seller in Q2 2024 was Point72 Asset Management, an estimated $668K sold.
Based on aggregated 13F filings for Q2 2024.